Literature DB >> 17576331

Clonality in the setting of Sweet's syndrome and pyoderma gangrenosum is not limited to underlying myeloproliferative disease.

Cynthia M Magro1, Bahram Kiani, Jingwei Li, A Neil Crowson.   

Abstract

BACKGROUND: The neutrophilic dermatoses encompass, among others, Sweet's syndrome (SS) and pyoderma gangrenosum (PG), which are associated with underlying systemic diseases including myeloid dyscrasias.
METHODS: On skin biopsies from 16 patients with biopsy-proven SS and/or PG, we performed an X-inactivation assay to detect clonal restriction of neutrophils. There were two patient categories based on known diseases at the time of diagnosis: patients with myeloproliferative disease and patients without myeloproliferative disease.
RESULTS: Among seven patients with acute myelogenous leukemia and two with myelodysplastic syndrome, clonal restriction was found in five; three were homozygous, precluding analysis. Among the seven control patients, infiltrates were clonally restricted in five; one was polyclonal and the other was homozygous for the allele, precluding analysis. Of the five patients with clonally restricted infiltrates, one was subsequently diagnosed with myelodysplasia, one had unexplained neutropenia and an additional patient developed breast cancer. Overall, the incidence of clonality in both groups was the same, averaging 81%.
CONCLUSION: These findings suggest that clonality in neutrophilic dermatoses, while characteristic of underlying myeloid dyscrasia, is not observed exclusively in the setting of myeloproliferative diseases. The significance of clonal neutrophilic infiltrates unassociated with myeloproliferative disease is unclear, but it may have some implications regarding the pathogenesis of sterile neutrophilic infiltrates. Clonality is well described in the setting of lymphomatoid hypersensitivity, reflecting an overzealous response to antigenic stimuli. One could speculate a similar mechanism operational in cases of apparently reactive SS/PG associated with monoclonality; a localized form of cutaneous neutrophilic dyscrasia is also possible.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576331     DOI: 10.1111/j.1600-0560.2006.00654.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  10 in total

Review 1.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

2.  Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.

Authors:  Syed M Kazmi; Naveen Pemmaraju; Keyur P Patel; Philip R Cohen; Naval Daver; Kathy M Tran; Farhad Ravandi; Madeleine Duvic; Guillermo Garcia-Manero; Sherry Pierce; Aziz Nazha; Gautam Borthakur; Hagop Kantarjian; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-12-24

3.  Clinicopathologic, Immunohistochemical, and Molecular Features of Histiocytoid Sweet Syndrome.

Authors:  Victoria Alegría-Landa; Socorro María Rodríguez-Pinilla; Angel Santos-Briz; José Luis Rodríguez-Peralto; Victor Alegre; Lorenzo Cerroni; Heinz Kutzner; Luis Requena
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

4.  Pyoderma gangrenosum - a guide to diagnosis and management .

Authors:  Christina George; Florence Deroide; Malcolm Rustin
Journal:  Clin Med (Lond)       Date:  2019-05       Impact factor: 2.659

5.  Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses.

Authors:  Andrew B Nesterovitch; Zsuzsa Gyorfy; Mark D Hoffman; Ellen C Moore; Nada Elbuluk; Beata Tryniszewska; Tibor A Rauch; Melinda Simon; Sewon Kang; Gary J Fisher; Katalin Mikecz; Michael D Tharp; Tibor T Glant
Journal:  Am J Pathol       Date:  2011-03-04       Impact factor: 4.307

6.  Characteristics of Sweet syndrome in patients with or without malignancy.

Authors:  Eun Hee Jung; Jin Hyun Park; Ki Hwan Kim; Jin-Soo Kim; In Sil Choi; Ja Min Byun; Youngil Koh; Dong-Yeop Shin; Junshik Hong; Sung-Soo Yoon; Hyunkyung Park; Inho Kim
Journal:  Ann Hematol       Date:  2022-04-28       Impact factor: 3.673

7.  Complete remission of Sweet's syndrome after azacytidine treatment for concomitant myelodysplastic syndrome.

Authors:  Sara Martinelli; Gian Matteo Rigolin; Genesio Leo; Roberta Gafà; Enrico Lista; Francesca Cibien; Olga Sofritti; Giulia Daghia; Francesco Cavazzini; Antonio Cuneo
Journal:  Int J Hematol       Date:  2014-02-20       Impact factor: 2.490

Review 8.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

Review 9.  Neutrophilic Dermatoses: a Clinical Update.

Authors:  Emma H Weiss; Christine J Ko; Thomas H Leung; Robert G Micheletti; Arash Mostaghimi; Sarika M Ramachandran; Misha Rosenbach; Caroline A Nelson
Journal:  Curr Dermatol Rep       Date:  2022-03-16

Review 10.  Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.

Authors:  Philip R Cohen
Journal:  Orphanet J Rare Dis       Date:  2007-07-26       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.